Cytosorbents Co. (NASDAQ:CTSO) Sees Significant Increase in Short Interest

Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 1,830,000 shares, an increase of 26.2% from the December 31st total of 1,450,000 shares. Based on an average daily volume of 262,700 shares, the short-interest ratio is currently 7.0 days.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on CTSO shares. StockNews.com began coverage on Cytosorbents in a report on Wednesday, January 29th. They set a "hold" rating for the company. D. Boral Capital reissued a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a report on Monday, January 13th. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $4.67.

Cytosorbents Trading Up 2.2 %

Shares of NASDAQ:CTSO traded up $0.02 during mid-day trading on Wednesday, reaching $1.01. 46,584 shares of the company's stock were exchanged, compared to its average volume of 437,533. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.59. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The firm has a market capitalization of $55.23 million, a price-to-earnings ratio of -2.81 and a beta of 0.61. The business's fifty day moving average price is $0.96 and its 200-day moving average price is $1.04.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last announced its earnings results on Thursday, November 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The firm had revenue of $9.39 million for the quarter, compared to the consensus estimate of $10.14 million. During the same period in the prior year, the business earned ($0.21) EPS. On average, research analysts predict that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Trading of Cytosorbents

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Sargent Investment Group LLC increased its position in shares of Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company's stock valued at $2,439,000 after acquiring an additional 192,747 shares during the last quarter. Atomi Financial Group Inc. bought a new stake in shares of Cytosorbents during the 3rd quarter worth $51,000. Finally, Skylands Capital LLC increased its stake in shares of Cytosorbents by 1.0% during the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after purchasing an additional 26,195 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.